Lysozyme-associated nephropathy (renal complications in MPN)

Current understanding

To be populated as evidence accumulates.

2026-04-27 — JAK Inhibitor-Induced Improvement of IgA Nephropathy in a Patient With Polycythemia Vera: A Case Report.: 2026 — Case report of IgA nephropathy improvement with ruxolitinib in PV expands the spectrum of MPN-associated renal complications responsive to JAK inhibition, distinct from LyN but sharing ruxolitinib as a stabilizing agent for renal function. (novelty: 4) (novelty: 4)
2026-06-16 — Lysozyme-Associated Nephropathy in Myeloid Neoplasms: A Clinicopathological and Mass Spectrometric Study of Two Cases.: Case-report series (n=2) including first reported LyN case in primary myelofibrosis with progressive monocytosis; first proteomic mass spectrometry analysis of affected proximal tubules implicates lysosomal homeostasis disruption, altered lipid metabolism, and cellular stress responses as mechanistic drivers of LyN pathophysiology. (novelty: 4)